Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer

Crizotinib, a first-line anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor, has shown promising results for the treatment of locally advanced and metastatic lung cancer presenting the ALK rearrangement. On the other hand, secondary organizing pneumonia (OP) caused by anti-cancer drugs has b...

Full description

Bibliographic Details
Main Authors: Nobuhiro Asai, Toyoharu Yokoi, Etsuro Yamaguchi, Akihito Kubo
Format: Article
Language:English
Published: Karger Publishers 2014-09-01
Series:Case Reports in Oncology
Subjects:
Lung cancer
Crizotinib
Organizing pneumonia
EML4-ALK
Online Access:http://www.karger.com/Article/FullText/366516

Internet

http://www.karger.com/Article/FullText/366516

Similar Items